Marathon Nextgen Realty Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 19, 2025, 3:13 am

Quick Insight

Marathon Nextgen Realty Ltd, operating in the Construction, Contracting & Engineering sector, currently trades at a price of 623 with a market cap of 4,196 Cr. The company's P/E stands at 20.0, indicating a moderate valuation, while ROE and ROCE are at 13.2% and 12.0% respectively, reflecting a decent profitability and efficiency. With an OPM of 22%, the company shows operational strength. Notably, the Promoters hold a significant stake of 55.93%, signaling confidence in the business. The healthy ICR of 4.58x suggests the company can comfortably meet its interest obligations. Overall, Marathon Nextgen Realty Ltd appears to be a fundamentally sound investment opportunity with strong financial metrics.

Competitors of Marathon Nextgen Realty Ltd

All Competitor Stocks of Marathon Nextgen Realty Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:15 am

Below is a detailed analysis of the quarterly data for Marathon Nextgen Realty Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 141.00 Cr.. The value appears to be declining and may need further review. It has decreased from 149.00 Cr. (Mar 2025) to 141.00 Cr., marking a decrease of 8.00 Cr..
• For Expenses, as of Jun 2025, the value is 110.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 107.00 Cr. (Mar 2025) to 110.00 Cr., marking an increase of 3.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 10.00 Cr..
• For OPM %, as of Jun 2025, the value is 22.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Mar 2025) to 22.00%, marking a decrease of 6.00%.
• For Other Income, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 11.00 Cr..
• For Interest, as of Jun 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 6.00 Cr..
• For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 62.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 6.00 Cr..
• For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 23.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 62.00 Cr., marking an increase of 8.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 11.69. The value appears strong and on an upward trend. It has increased from 10.41 (Mar 2025) to 11.69, marking an increase of 1.28.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:49 pm

Balance Sheet

Last Updated: September 10, 2025, 2:03 pm

Below is a detailed analysis of the balance sheet data for Marathon Nextgen Realty Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,161.00 Cr.. The value appears strong and on an upward trend. It has increased from 980.00 Cr. (Mar 2024) to 1,161.00 Cr., marking an increase of 181.00 Cr..
• For Borrowings, as of Mar 2025, the value is 560.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 761.00 Cr. (Mar 2024) to 560.00 Cr., marking a decrease of 201.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 350.00 Cr.. The value appears to be improving (decreasing). It has decreased from 482.00 Cr. (Mar 2024) to 350.00 Cr., marking a decrease of 132.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,097.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,248.00 Cr. (Mar 2024) to 2,097.00 Cr., marking a decrease of 151.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 237.00 Cr.. The value appears to be declining and may need further review. It has decreased from 286.00 Cr. (Mar 2024) to 237.00 Cr., marking a decrease of 49.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 29.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,750.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,881.00 Cr. (Mar 2024) to 1,750.00 Cr., marking a decrease of 131.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,097.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,248.00 Cr. (Mar 2024) to 2,097.00 Cr., marking a decrease of 151.00 Cr..

Notably, the Reserves (1,161.00 Cr.) exceed the Borrowings (560.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Marathon Nextgen Realty Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 37.21. This value is within the healthy range. It has increased from 34.43 (Mar 24) to 37.21, marking an increase of 2.78.
• For Diluted EPS (Rs.), as of Mar 25, the value is 37.19. This value is within the healthy range. It has increased from 32.50 (Mar 24) to 37.19, marking an increase of 4.69.
• For Cash EPS (Rs.), as of Mar 25, the value is 32.25. This value is within the healthy range. It has increased from 26.71 (Mar 24) to 32.25, marking an increase of 5.54.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 234.85. It has increased from 196.85 (Mar 24) to 234.85, marking an increase of 38.00.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 234.85. It has increased from 196.85 (Mar 24) to 234.85, marking an increase of 38.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 113.29. It has decreased from 137.70 (Mar 24) to 113.29, marking a decrease of 24.41.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 52.59. This value is within the healthy range. It has decreased from 53.56 (Mar 24) to 52.59, marking a decrease of 0.97.
• For PBIT / Share (Rs.), as of Mar 25, the value is 52.07. This value is within the healthy range. It has decreased from 52.98 (Mar 24) to 52.07, marking a decrease of 0.91.
• For PBT / Share (Rs.), as of Mar 25, the value is 40.60. This value is within the healthy range. It has increased from 35.21 (Mar 24) to 40.60, marking an increase of 5.39.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 31.73. This value is within the healthy range. It has increased from 26.13 (Mar 24) to 31.73, marking an increase of 5.60.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 36.43. This value is within the healthy range. It has increased from 32.53 (Mar 24) to 36.43, marking an increase of 3.90.
• For PBDIT Margin (%), as of Mar 25, the value is 46.42. This value is within the healthy range. It has increased from 38.89 (Mar 24) to 46.42, marking an increase of 7.53.
• For PBIT Margin (%), as of Mar 25, the value is 45.96. This value exceeds the healthy maximum of 20. It has increased from 38.47 (Mar 24) to 45.96, marking an increase of 7.49.
• For PBT Margin (%), as of Mar 25, the value is 35.83. This value is within the healthy range. It has increased from 25.56 (Mar 24) to 35.83, marking an increase of 10.27.
• For Net Profit Margin (%), as of Mar 25, the value is 28.00. This value exceeds the healthy maximum of 10. It has increased from 18.97 (Mar 24) to 28.00, marking an increase of 9.03.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 32.15. This value exceeds the healthy maximum of 20. It has increased from 23.62 (Mar 24) to 32.15, marking an increase of 8.53.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has decreased from 16.71 (Mar 24) to 15.51, marking a decrease of 1.20.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.77. This value is within the healthy range. It has increased from 16.11 (Mar 24) to 16.77, marking an increase of 0.66.
• For Return On Assets (%), as of Mar 25, the value is 8.89. This value is within the healthy range. It has increased from 7.43 (Mar 24) to 8.89, marking an increase of 1.46.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.31, marking a decrease of 0.27.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.46. This value is within the healthy range. It has decreased from 0.76 (Mar 24) to 0.46, marking a decrease of 0.30.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.26. It has decreased from 0.32 (Mar 24) to 0.26, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.15, marking an increase of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.86, marking a decrease of 0.04.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 2.82 (Mar 24) to 0.00, marking a decrease of 2.82.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 2.77 (Mar 24) to 0.00, marking a decrease of 2.77.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 97.18 (Mar 24) to 0.00, marking a decrease of 97.18.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 97.23 (Mar 24) to 0.00, marking a decrease of 97.23.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.58. This value is within the healthy range. It has increased from 3.01 (Mar 24) to 4.58, marking an increase of 1.57.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.76. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 3.76, marking an increase of 1.29.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,106.71. It has decreased from 3,295.87 (Mar 24) to 3,106.71, marking a decrease of 189.16.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.36. This value exceeds the healthy maximum of 3. It has increased from 4.68 (Mar 24) to 5.36, marking an increase of 0.68.
• For EV / EBITDA (X), as of Mar 25, the value is 11.54. This value is within the healthy range. It has decreased from 12.03 (Mar 24) to 11.54, marking a decrease of 0.49.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 3.71 (Mar 24) to 4.55, marking an increase of 0.84.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 97.17 (Mar 24) to 0.00, marking a decrease of 97.17.
• For Price / BV (X), as of Mar 25, the value is 2.19. This value is within the healthy range. It has decreased from 2.63 (Mar 24) to 2.19, marking a decrease of 0.44.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 3.71 (Mar 24) to 4.55, marking an increase of 0.84.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness